app

(redirected from beta-amyloid peptide)
Also found in: Dictionary, Medical, Financial, Wikipedia.

app

app

(1) (APPlication) The file extension for executable Mac applications. See APP file.

(2) (APPlication) The term has been shorthand for "application" in the IT community for a long time. However, it became popular with the consumer for mobile applications in smartphones and tablets after Apple debuted the iPhone 3G in 2008. It is just as correct to say "iPhone application" as it is "desktop computer app;" although app is shorter, and computer people love to abbreviate. See application and online app store.

(3) (APPlication) In the engineering world, an app can refer to a circuit design, using the word "application" in the context of purpose. For example, "high-voltage apps" means high-voltage circuit designs. The term predates mobile software apps by decades.


Apps Are Everywhere
After installing a new smart TV, as in this Samsung 4K TV example in 2016, users have the option of downloading apps from Netflix, Amazon and other content providers.







And We Do Mean "Everywhere"
For decades the word "apps" have been shorthand for "appetizers" and it still is.
References in periodicals archive ?
Studies in AD transgenic mice show that the binding of beta-amyloid peptides to ABAD prevents the normal function of ABAD and leads to enhanced production of free radicals followed by increased apoptosis.
Hock and his team took an additional step by calculating the ratio of tau protein to beta-amyloid peptide and found that Alzheimer's patients averaged 147 times as much of the protein as the peptide, whereas healthy people averaged only 39 times as much.
IGIV therapy may contain antibodies that possibly have strong binding characteristics to several aggregated forms of the beta-amyloid peptide that are believed to cause Alzheimer's disease," said Dr.
Central to the development of Alzheimer's disease is beta-amyloid peptide, a substance normally produced in the brain but which in Alzheimer's is deposited abnormally.
The deposition of beta-amyloid peptide in the brain is believed to be a central event in the development of Alzheimer's disease.
The beta-amyloid peptide Ass-42 (the main component of amyloid plaques in AD patients) is the AD target that has received the most attention from drug developers, and drugs targeting amyloid are the disease-modifying therapies furthest along in development.
One of the characteristics of Alzheimer's disease is the presence, in the brain, of senile plaques composed of beta-amyloid peptide aggregates.
Excessive accumulation in the brain of the beta-amyloid peptide, due either to overproduction and/or decreased clearance and the formation of senile plaques, is one of the hallmarks of Alzheimer disease.
Tau-related tangles and beta-amyloid peptide related plaques are the two known pathologies associated with Alzheimer's disease.
Elan has been at the forefront of Alzheimer's disease research for almost two decades, in particular in advancing the understanding of the beta-amyloid peptide - A-beta - that is the main building block of amyloid plaques, which are a hallmark of Alzheimer's disease neuropathology.
The major constituent of the senile plaques associated with Alzheimer's diseases is the beta-amyloid peptide, generated by the activity of the enzyme beta-secretase in the human brain.
The first is active immunization with a segment of the beta-amyloid peptide, which triggers an immune response and the generation of antibodies, with the goal of reducing the level of beta-amyloid in the brain, and second, passive immunization (antibody administration) specific to the beta-amyloid peptide.